Generation and characterization of in vivo models of Small Fiber Neuropathy
Generation and characterization of in vivo models of Small Fiber Neuropathy
批准号:
8818922
负责人:
Joel Black
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-10-01 至 2016-09-30
关键词:
AddressAdultAffectAgeAgingAlcoholismAutoimmune DiseasesAutonomic DysfunctionAxonBehavioralBurn injuryCarbamazepineCellsChimera organismCloningContractsCustomDevelopmentDiabetes MellitusDiseaseDysautonomiasExhibitsFiberFundingFutureGenerationsGenesGoalsHIVHIV InfectionsHandHealthHumanIdiopathic NeuropathyIn VitroIncidenceInflammatoryKnock-in MouseLaboratoriesLengthLinkMechanicsMedicalMethodsMolecularMusMutationNerve FibersNeuritesNeurodegenerative DisordersNeuronsNeuropathyNumbnessPainPathway interactionsPatientsPeripheral NervesPhenotypePopulationPrevalenceRefractoryResearch Project GrantsSensoryServicesSodium ChannelSodium Channel BlockersSwellingSymptomsTestingToxinUnited StatesVariantVeteransVisceral painagent orangeappendageaxonal degenerationbasebiophysical propertiescostdensitydesignfootgain of functionin vivo Modelmouse modelneoplasticnovel therapeutic interventionpatch clampprobandpublic health relevancespontaneous painvectorvoltage
中文摘要
描述(由申请人提供):
小纤维神经病(SFN)是一种神经退行性疾病,其特征在于无髓鞘C-、小髓鞘Ad-和自主神经纤维的损失,并且与感觉和自主神经功能障碍相关,包括烧灼感、针刺痛和刺痛以及自主神经症状,其通常难以治疗。 SFN与多种原因有关,包括糖尿病、酒精中毒、毒素(包括橙子剂)、HIV、抗肿瘤治疗和自身免疫性疾病,但相当大比例的SFN是特发性的,没有明显的原因。 我们最近证实了近30%的SFN患者存在钠通道Nav1.7的功能获得性变体,并且没有其他明显的原因。 然而,导致与Nav1.7中的功能获得变体相关的小纤维损失和疼痛发作的分子级联,或与SFN相关的多种原因中的任何一种,尚未被理解。 拟定的小项目旨在通过在Scn 9a等位基因的Scn 9a(Nav1.7)基因中杂合插入人功能获得性变体来创建敲入小鼠,从而开发小纤维神经病的体内模型。 在特发性SFN患者中发现了Nav1.7中的多种功能获得性变体,我们对两种变体(I228 M和G856 M)的电生理和形态学研究是非常有希望的候选者,可用于体内模型的生成。对于我们的研究,基因敲入小鼠的产生和表型特征的形态学,全细胞膜片钳和行为的方法。 在未来的研究中,敲入小鼠将作为有价值的平台,在其中进行机制研究,以确定导致轴突变性的分子途径以及SFN中感觉和自主神经功能障碍的发作。 还预计体内模型的开发将使我们能够识别和测试新的治疗方法,以最大限度地减少人类小纤维神经病中轴突变性以及与纤维损失相关的感觉和自主神经功能障碍。
英文摘要
DESCRIPTION (provided by applicant):
Small fiber neuropathy (SFN) is a neurodegenerative disorder that is characterized by a loss of unmyelinated C-, small myelinated Ad- and autonomic fibers, and is associated with sensory and autonomic dysfunctions, including burning, pin-prick and lancinating pain and autonomic symptoms, which are often refractory to treatment. SFN has been linked to multiple causes, including diabetes, alchoholism, toxins, including Agent Orange, HIV, anti-neoplastic treatments, and autoimmune disorders, but a substantial percentage of SFN are idiopathic, with no apparent cause. We have recently demonstrated the presence of gain-of-function variants in sodium channel Nav1.7 in nearly 30% of patients with SFN and no other apparent cause. However, the molecular cascade leading to small fiber loss and onset of pain associated with the gain- of-function variants in Nav1.7, or any of the multiple causes linked to SFN, is not yet understood. The proposed Small Project is designed to develop an in vivo model of small fiber neuropathy by creating knock-in mice with heterozygous insertion of a human gain-of-function variant in the Scn9a (Nav1.7) gene at the Scn9a allelle. Multiple gain-of-function variants in Nav1.7 have been found in patients with idiopathic SFN, and our electrophysiological and morphological studies of two variants (I228M and G856M) as exceptionally promising candidates in which to pursue generation of in vivo models. For our studies, knock-in mice are generated and phenotypically characterized by morphological, whole-cell patch clamp and behavioral methods. In future studies not funded by this proposal, the knock-in mice will serve as valuable platforms in which to perform mechanistic studies to determine the molecular pathway(s) leading to axonal degeneration and the onset of sensory and autonomic dysfunction in SFN. It is also anticipated that the development of the in vivo models will allow us to identify and test novel therapeutic approaches to minimize axonal degeneration, and the sensory and autonomic dysfunctions associated with fiber loss, in human small fiber neuropathy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金